eligibility_summary
Key inclusion: age 18–70, recurrent/progressive WHO grade 3–4 glioma with ≥1 evaluable lesion, tissue ≤6 mo showing B7‑H3+, KPS ≥60, life expectancy >3 mo, adequate marrow/liver/renal labs, EF >55%, neg pregnancy test/contraception, consent. Exclude: pregnancy/lactation, major organ failure, second cancer, active HBV/HCV/HIV/infection, severe autoimmune/unstable disease, systemic steroids or immuno/hormone therapy, allergy to immunotherapy, transplant history/awaiting, other trials <30 d, per PI.
trial_source
clinical_trials.gov from Dec 2, 2025
annotation_status
ai
ai_summary
Intervention: QH104, an allogeneic B7‑H3 (CD276) chimeric antigen receptor γδ T‑cell therapy (cellular immunotherapy). Mechanism: Donor-derived γδ T cells are engineered with a CAR that binds B7‑H3, engagement triggers MHC‑independent activation and cytotoxic killing (perforin/granzyme, cytokines), enabling off‑the‑shelf use with low GVHD risk. Administration is intrathecal/Ommaya for CNS delivery. Targets: B7‑H3 overexpressed on high‑grade glioma/GBM cells and tumor‑associated vascular endothelial cells, the therapy aims at tumor cells and tumor vasculature within the glioma microenvironment, countering B7‑H3–driven immune evasion and pro‑angiogenic signaling. Trial design: open‑label, single‑arm, phase 1/2 dose‑escalation/expansion in recurrent/progressive HGG.